Skip to main content

One opioid drugmaker's solution to billions of potential liabilities: spin them out into new company

Mallinckrodt Pharmaceuticals plans to separate its business into two: one with its brand-name medicines; the other with its specialty generic drugs — including ooxycodone and hydrocodone.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.